A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa
Key facts
- Where
- Athens, Larissa, Piraeus, and Thessaloniki, GreeceSee the 6 sites
Where in Greece
- General Hospital Andreas Syggros /ID# 276969Athens, GreeceContact: Beth RycroftTaking people
- University General Hospital Attikon /ID# 278395Athens, GreeceContact: Beth RycroftTaking people
- The University Hospital of Larissa /ID# 277234Larissa, GreeceContact: Beth RycroftTaking people
- Tzaneio Prefecture General Hospital of Piraeus /ID# 276881Piraeus, GreeceContact: Beth RycroftTaking people
- Hospital of Skin and Venereal Diseases- Thessaloniki /ID# 277278Thessaloniki, GreeceContact: Beth RycroftTaking people
- Papageorgiou General Hospital /ID# 277450Thessaloniki, GreeceContact: Beth RycroftTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- AbbVie
- Trial code
- NCT07136467
- Record updated
- 13 February 2026
- Original description
This study is to assess the burden of disease in adolescent and adult participants with moderate or severe alopecia areata (AA), non-segmental vitiligo (NSV), or moderate to severe hidradenitis suppurativa (HS) in a large global real-world participant population.Read full original descriptionShow less
Multi-Country, Cross-sectional Study to Characterize Real World Burden of Disease in Adolescent and Adult Patients With Alopecia Areata, Vitiligo or Hidradenitis Suppurativa (MEASURE AAVitHS)
This study is to assess the burden of disease in adolescent and adult participants with moderate or severe alopecia areata (AA), non-segmental vitiligo (NSV), or moderate to severe hidradenitis suppurativa (HS) in a large global real-world participant population.
Inclusion: Participants with Physician-confirmed diagnosis of non-segmental vitiligo (NSV), moderate to severe Alopecia Areata (AA), or moderate to severe hidradenitis suppurativa (HS); Participants Ability to understand study questionnaires, with caregiver support as required for adolescents.
Exclusion: Participating in interventional clinical trial(s) at time of study visit (participation in another non-interventional study or registry does not exclude a participant from this study); Unable or unwilling to comply with study requirements and PRO collection.